Magnesium Sulfate Administration Guidelines

Introduction to Magnesium Sulfate Risks

• The American Heart Association notes that magnesium produces vasodilation and may cause hypotension if administered rapidly, particularly in patients with certain conditions such as hypovolemia, renal impairment, or pre-existing cardiovascular disease 1

Patient Risk Factors

• Patients with hypovolemia, renal impairment, or those receiving concomitant CNS depressants or vasodilators are at increased risk of hypotension when administered magnesium sulfate 1

Clinical Manifestations of Hypermagnesemia

• Cardiovascular manifestations of hypermagnesemia include vasodilatation, hypotension, bradycardia, and heart block, as noted by clinical guidelines 2

Administration Precautions

• To minimize the risk of hypotension when administering 2g of magnesium sulfate over 30 minutes, ensure adequate hydration status, monitor blood pressure continuously, and have calcium immediately available as an antidote, as recommended by clinical guidelines 2

Management of Hypotension

• If hypotension occurs during or after magnesium sulfate administration, slow or temporarily stop the infusion, position the patient supine with legs elevated, administer IV fluids, and consider administering calcium as a physiological antagonist or vasopressors for refractory hypotension 2